EGFR exon 20 insertion mutations
© PSI, 1995 – 2021. All rights reserved
The combination was compared to chemotherapy alone. The study hit the primary OS endpoint and all critical secondary endpoints.
KRAS G12C mutations
KRAS G12C mutations account for approximately 13% of lung adenocarcinomas, and thus new treatment options are needed to fill an unmet need:
Adragrasib demonstrated positive results in patients with advanced NSCLC harboring the KRASG12C mutation after previous systemic therapy (immunotherapy or chemotherapy), showing an ORR of 45% and DCR of 80% [48].
Other
According to the new research, patients with metastatic NSCLC enrolled in a clinical trial had a median survival that was nearly double that of those not enrolled. Further, patients enrolled in a clinical trial had an almost 50% lower risk of death.